Traws Pharma grants 14,150 stock options to director

Traws Pharma, Inc. director Werner Cautreels received a grant of stock options to acquire 14,150 shares of common stock at an exercise price of $0.68 per share.

Accepted by SEC EDGAR 07/15/2026 - 09:32 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Traws Pharma, Inc. director Werner Cautreels received a grant of stock options to acquire 14,150 shares of common stock at an exercise price of $0.68 per share. The options, granted on July 9, 2026 under the 2021 Incentive Compensation Plan, vest 100% after one year and expire on July 9, 2036, leaving him holding options for 14,150 shares directly.

Insider Trade Summary

Grant/Award: 14,150 shares

Grant/Award 1 txn

Insider CAUTREELS WERNER

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	14,150	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 14,150 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 14,150 contracts (Direct)

Footnotes (1)

1. F1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

Key Figures

Stock options granted: 14,150 options Exercise price: $0.68 per share Underlying common shares: 14,150 shares +2 more

5 metrics

Stock options granted 14,150 options Grant to director Werner Cautreels on July 9, 2026

Exercise price $0.68 per share Exercise price of director stock option award

Underlying common shares 14,150 shares Common stock underlying granted options

Expiration date July 9, 2036 End of exercise period for stock option grant

Options held after grant 14,150 options Total derivative holdings reported following the transaction

Key Terms

Stock Option (right to buy), exercise price, 2021 Incentive Compensation Plan, vesting

4 terms

Stock Option (right to buy) financial

"Security title listed as Stock Option (right to buy)"

exercise price financial

"Conversion or exercise price of $0.6800 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2021 Incentive Compensation Plan financial

"Awarded under the Issuer's 2021 Incentive Compensation Plan"

vesting financial

"Stock options under this award will vest 100% on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did Traws Pharma (TRAW) grant to director Werner Cautreels?

Werner Cautreels received a grant of 14,150 stock options to purchase Traws Pharma common shares. The options were awarded on July 9, 2026 as director compensation under the company’s 2021 Incentive Compensation Plan.

What is the exercise price of Werner Cautreels’ new Traws Pharma (TRAW) stock options?

The granted stock options have an exercise price of $0.68 per share. This means Cautreels can buy up to 14,150 shares of Traws Pharma common stock at $0.68 once the options are vested and exercisable.

When do Werner Cautreels’ Traws Pharma (TRAW) stock options vest and expire?

The stock options vest 100% on the first anniversary of the July 9, 2026 grant date. They have an expiration date of July 9, 2036, giving Cautreels a 10-year window after grant to exercise once vested.

How many Traws Pharma (TRAW) options does Werner Cautreels hold after this grant?

Following the reported grant, Werner Cautreels holds stock options covering 14,150 shares of Traws Pharma common stock directly. This reflects the full amount of the July 9, 2026 award reported in the Form 4.

Was Werner Cautreels’ Traws Pharma (TRAW) option grant an open-market transaction?

No, the transaction was a grant of stock options as director compensation, not an open-market trade. The options were awarded by Traws Pharma’s compensation committee under the 2021 Incentive Compensation Plan at an exercise price of $0.68 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAUTREELS WERNER

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC

12 PENNS TRAIL

(Street)

NEWTOWN PENNSYLVANIA 18940

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.68	07/09/2026		A		14,150		07/09/2027(1)	07/09/2036	Common Stock	14,150	$0	14,150	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ Werner Cautreels	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)